Press releases
- CSL Vifor and Travere Therapeutics Announce European Commission approves FILSPARI® (sparsentan) for the treatment of IgA Nephropathy
- Ferinject® approved by Health Canada for the treatment of iron deficiency anemia in adult and pediatric patients and iron deficiency in adult patients with heart failure
- Half year reported NPATA US$2 billion¹,² Up 13% at constant currency³
Key statistics
On Thursday, CSL Ltd (CSJA:DUS) closed at 84.00, -1.75% below its 52-week high of 85.50, set on Apr 12, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 83.50 |
---|---|
High | 84.00 |
Low | 83.50 |
Bid | 84.00 |
Offer | 85.50 |
Previous close | 84.00 |
Average volume | 11.11 |
---|---|
Shares outstanding | -- |
Free float | -- |
P/E (TTM) | -- |
Market cap | -- |
EPS (TTM) | -- |
Data delayed at least 15 minutes, as of May 09 2024 18:58 BST.
More ▼